If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

If the trial is successful, the firm's complete estrogen receptor antagonist would complement its other biomarker-driven breast cancer assets.

Compared with endocrine therapy, radiotherapy was associated with a smaller reduction in health-related quality-of-life in ...

Eating well can help support your immune system and maintain strength and energy if you have HER2-negative breast cancer, ...

Cell cycle re-entry of senescent breast cancer cells after CDK4/6 inhibition (CDK4/6i) constitutes a major source of disease ...

The new approval covers Kisqali's use in combination with an aromatase inhibitor (AI) in patients with HR+/HER2- early breast cancer at high risk of recurrence. Previously, the drug was approved ...

STX-478 is a once-daily oral, mutant-selective PI3Kα inhibitor currently being evaluated ... (ABC), whose disease progressed on a prior aromatase inhibitor (AI), with or without a CDK4/6 inhibitor.

Reproductive steroids are powerful hormones that play a key role in the growth and development of our bodies, especially during puberty.

Anthos Therapeutics is a clinical-stage biopharmaceutical company developing abelacimab, a potential first-in-class monoclonal antibody targeting the FXI inhibition pathwayAbelacimab is currently ...